查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2016886

转录组学技术市场：按产品类型、技术、应用和最终用户划分－2026-2032年全球市场预测

Transcriptomics Technologies Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，转录组学技术市场价值将达到 83.9 亿美元，到 2026 年将成长至 87.9 亿美元，到 2032 年将达到 119.3 亿美元，复合年增长率为 5.15%。

主要市场统计数据
基准年 2025 83.9亿美元
预计年份：2026年 87.9亿美元
预测年份 2032 119.3亿美元
复合年增长率 (%) 5.15%

这是一本权威的入门书籍，它将现代转录组学技术定位为研究应用、临床创新和产业战略转型的重要支柱。

转录组学处于分子层级洞察与转化应用机会的交汇点，它正在改变研究人员、临床医生和产业创新者大规模、精准地分析基因表现的方式。定序平台、试剂化学和生物资讯学流程的进步，已将分析分辨率从组织层面的简介扩展到高分辨率的单细胞水平，从而能够提出关于新型生物标誌物和机制的假设，这些假设将直接促进药物发现、临床诊断和个人化医疗的发展。本书系统性地说明了影响产品开发、采购和转化研究策略决策的技术、能力和相关人员的优先事项。

详细概述了技术、营运和伙伴关係主导的变革，这些变革正在重新定义转录组学研究和应用领域的竞争力。

转录组学领域正经历着一场变革浪潮，其驱动力来自于技术进步的融合、分析需求的不断变化以及科研和临床环境中操作重点的转变。新型高通量平台和桌上型定序仪正在提升处理能力并缩短结果获取时间。同时，试剂和样品製备盒的化学性质也日趋稳定，从而能够支持更广泛的样本类型并减少所需的起始样本量。此外，高空间分辨率的原位杂合反应技术在表达分析研究中重新焕发活力，它与基于定序的方法相辅相成，并拓展了生物学可观察的边界。

对美国将于 2025 年前实施的关税政策如何重塑转录组学领域的采购、供应链和投资决策进行全面分析。

美国已宣布并于2025年前实施的关税措施的累积影响，正在波及整个转录组学生态系统的筹资策略、供应商关係和供应链结构。进口设备和试剂关税带来的成本压力，促使许多采购者重新评估采购惯例。采购团队越来越关注供应商的来源、组件层面的风险以及总到岸成本，而不仅限于单价。因此，各机构正在实现供应商组合多元化，并探索利用区域供应商来降低贸易政策波动带来的风险。

透过对产品、技术、应用和最终用户进行详细分析，揭示转录组学领域能力差距和价值创造的交汇点。

细分市场层面的趋势揭示了每种产品类型、技术、应用和最终用户群所面临的不同机会和营运考量，这些因素应指南策略规划和资源分配。就产品类型而言，本平台涵盖桌上型定序仪和高通量定序仪，二者分别满足不同的处理能力和性价比需求。桌上型仪器适用于分散式实验室和诊断工作流程，因为这些场景对快速週转和简化的工作流程要求极高；而高通量定序仪则适用于大规模药物研发专案和多样检体临床研究，因为这些专案对单样本成本和仪器处理能力要求极高。试剂和耗材包括 cDNA 合成试剂盒、RNA 萃取试剂盒和定序盒。每类产品都需满足严格的品质和批间一致性要求，这些要求直接影响下游资料的完整性。软体和服务包括资料分析软体和资料管理服务，它们共同构成了一个可重复且可审计的流程基础，该流程对于研究间的比较以及产生符合监管要求的证据至关重要。

美洲、欧洲、中东和非洲以及亚太地区的基础设施、监管预期和部署路径存在细微的区域差异。

区域趋势正在影响转录组学领域的基础设施投资、监管预期和伙伴关係机会，而对美洲、欧洲、中东和非洲以及亚太地区的深入了解对于有效进入市场至关重要。在美洲，成熟的研究机构和紧密的生物技术生态系统持续推动高通量定序和高阶分析的需求。同时，临床网路内的转化医学计画和倡议医疗计画也催生了对检验的工作流程和整合资料管理解决方案的需求。该地区还拥有大规模的试剂生产能力和充满活力的供应商体系，这些都为技术的快速应用提供了支持。

在转录组学领域，平台、试剂和软体提供者之间观察到的清晰策略趋势揭示了竞争差异化和伙伴关係模式的演变。

在转录组学生态系统中运作的公司正在推行差异化策略，以反映其在平台、试剂或软体服务方面的核心优势。这些策略选择凸显了未来的竞争格局和伙伴关係机会。平台供应商正致力于提升仪器的模组化、扩充性和易用性，以适应不同的实验室环境并降低用户采用门槛。那些能够展现仪器在各种样本类型中稳定性能，并能提供整合耗材生态系统的公司，相比那些寻求能够最大限度降低技术风险的承包解决方案的客户，拥有竞争优势。

为产业领导者提供可操作的策略建议，以加强供应链韧性、加快部署速度，并使产品蓝图与应用主导的需求保持一致。

行业领导者应采取一系列切实可行的措施，以保持韧性并在不断发展的转录组学领域中获取价值。首先，他们应优先考虑供应商多元化和资质认证流程，该流程不仅评估价格和前置作业时间，还评估地域贸易政策风险、生产冗余以及合格体系成熟度。投资关键试剂和耗材的双源策略可以降低单点故障 (SPOF) 的风险，并增强采购谈判中的议价能力。同时，符合法规和品质指标的供应商评分卡有助于快速合格。

我们要求对本报告中用于得出研究结果的混合研究途径做出透明的解释，该方法结合了对主要相关人员的访谈、技术三角验证和供应链情境分析。

本研究采用混合方法，旨在捕捉影响转录组学应用的技术细节、营运动态和策略应对措施。主要资讯来源包括与学术界、受託研究机构(CRO)、医院和诊断检查室以及製药和生物技术公司等相关人员的结构化访谈和专题讨论，从而获得有关采购重点、工作流程挑战和验证要求的第一手观点。这些对话与二手研究（包括同行评审的科学文献、行业白皮书、监管指导文件和供应商技术规范）进行交叉比对，以检验技术声明和性能特征。

这项简明结论总结了整合解决方案、供应商韧性和资料管治对于不断发展的转录组学领域取得成功的关键作用。

总之，转录组学技术正从小众研究工具发展成为一项基础性能力，推动广泛的科学和临床进步。平台、试剂和软体的相互作用，正在建构一个需要整合解决方案和严格资料管治的环境，以充分发挥基因表现分析的转化潜力。随着应用范围的扩大，相关人员必须在技术选择上权衡通量、灵敏度和操作复杂性，同时将检验、可重复性和供应商稳定性作为核心优先事项。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：转录组学技术市场：依产品类型划分

  • 平台
    • 桌上型音序器
    • 高通量定序仪
  • 试剂和耗材
    • cDNA合成试剂盒
    • RNA萃取试剂盒
    • 定序盒
  • 软体服务
    • 数据分析软体
    • 资料管理服务

第九章：转录组学技术市场：依技术分类

  • 原位杂合反应
  • 次世代定序
  • 定量即时PCR

第十章 转录组学技术市场：依应用领域划分

  • 生物标记发现
  • 药物发现与开发
  • 基因表现分析
    • 批量表达谱分析
    • 单细胞表现谱分析
  • 个人化医疗

第十一章 转录组学技术市场：依最终使用者划分

  • 学术和研究机构
  • 合约研究机构
  • 医院和诊断检测机构
  • 製药和生物技术公司

第十二章 转录组学技术市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 转录组学技术市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 转录组学技术市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国转录组学技术市场

第十六章：中国转录组学技术市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 10x Genomics, Inc.
  • Agilent Technologies, Inc.
  • Akoya Biosciences, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Bruker Corporation
  • Carl Zeiss AG
  • Fluidigm Corporation
  • Illumina, Inc.
  • Oxford Nanopore Technologies Limited
  • Pacific Biosciences of California, Inc.
  • QIAGEN NV
  • Roche Holding AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-031685195774

The Transcriptomics Technologies Market was valued at USD 8.39 billion in 2025 and is projected to grow to USD 8.79 billion in 2026, with a CAGR of 5.15%, reaching USD 11.93 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.39 billion
Estimated Year [2026] USD 8.79 billion
Forecast Year [2032] USD 11.93 billion
CAGR (%) 5.15%

An authoritative introduction that situates modern transcriptomics technologies as transformative pillars for research translation, clinical innovation, and industrial strategy

Transcriptomics stands at the intersection of molecular insight and translational opportunity, transforming how researchers, clinicians, and industry innovators interrogate gene expression at scale and with precision. Advances in sequencing platforms, reagent chemistry, and bioinformatic pipelines have expanded analytical resolution from bulk tissue snapshots to high-resolution single-cell landscapes, enabling new classes of biomarkers and mechanistic hypotheses that directly inform drug discovery, clinical diagnostics, and personalized medicine. This introduction frames the technologies, capabilities, and stakeholder priorities that shape strategic decisions across product development, procurement, and translational research.

Over recent years, technological maturation has reduced many historic barriers to entry while simultaneously raising the bar for data quality and reproducibility. As platforms deliver higher throughput and reagents evolve to preserve sample integrity under diverse workflows, investigators must balance cost, turnaround, and analytic fidelity. Meanwhile, software and data management services are evolving from auxiliary tools to mission-critical infrastructure that underpins regulatory compliance, cross-study integration, and collaboration. Together, these dynamics compel organizations to reassess investment priorities, partnerships, and operational models to stay competitive and translationally relevant.

In this context, stakeholders must navigate complex trade-offs among platform performance, reagent robustness, and software capabilities, and align those choices with application-specific needs such as biomarker discovery, gene expression profiling, and drug development. The subsequent sections offer a focused synthesis of transformative market shifts, policy impacts, segmentation intelligence, regional nuances, company strategies, and practical recommendations designed to inform strategic planning and operational execution in the evolving transcriptomics landscape.

A detailed synthesis of the technological, operational, and partnership-driven shifts that are redefining competitiveness in transcriptomics research and applications

The transcriptomics landscape is undergoing a wave of transformative shifts driven by converging technological advances, evolving analytical expectations, and changing operational priorities within research and clinical environments. Newer high-throughput platforms and benchtop sequencers are expanding capacity and reducing time-to-result, while reagent chemistries and library preparation kits have become more robust, enabling broader sample types and reduced input requirements. Concurrently, in situ hybridization techniques are experiencing renewed interest for spatially resolved expression studies, complementing sequencing-based approaches and pushing the boundaries of what is biologically observable.

At the same time, data analysis software and data management services are gaining prominence as essential enablers of reproducible science. Workflow standardization, cloud-native pipelines, and integrated laboratory informatics are facilitating cross-institutional studies and longitudinal data aggregation. These software capabilities are also catalyzing collaborations across academia, contract research organizations, and biopharma, where harmonized data processing becomes a prerequisite for multi-center trials and regulatory submissions. In addition, an increasing emphasis on single-cell expression profiling is reshaping reagent demand and sequencing throughput requirements, necessitating combined investments in specialized kits and high-throughput sequencers to meet experimental complexity.

Strategic partnerships and vertical integration are emerging as competitive levers. Platform providers collaborating with reagent suppliers and analytics firms can offer more cohesive solutions that reduce adoption friction. Moreover, end users are demonstrating a preference for turnkey offerings that lower internal operational overhead while guaranteeing quality. These shifts collectively signal a move from component-based procurement toward solution-oriented engagements, reshaping supplier selection criteria and shaping the future of transcriptomics deployment across research and clinical settings.

A comprehensive analysis of how United States tariff policies implemented through 2025 are reshaping procurement, supply chains, and investment decisions in transcriptomics

The cumulative effects of United States tariffs announced and implemented through 2025 are influencing procurement strategies, supplier relationships, and supply chain configurations across the transcriptomics ecosystem. Tariff-driven cost pressures on imported equipment and reagents have prompted many buyers to re-evaluate sourcing practices, with procurement teams increasingly scrutinizing supplier origins, component-level exposures, and total landed cost rather than focusing solely on unit price. As a result, organizations are pursuing diversified supplier portfolios and exploring regional vendors to mitigate exposure to trade policy volatility.

In addition to direct cost implications, tariffs have altered the cadence of capital investment decisions for sequencing platforms. Institutions that previously planned multi-year upgrade cycles are now factoring potential customs duties and longer lead times into financing models, which can delay adoption of next-generation instruments. To manage these risks, a number of research organizations and larger commercial buyers are negotiating longer-term agreements with suppliers, including service contracts and bundled reagent commitments, to stabilize pricing and guarantee spare parts availability despite tariff-induced market uncertainty.

Tariffs have also accelerated conversations about nearshoring and contract manufacturing for critical reagents and consumables. Stakeholders recognize that relocating production or qualifying secondary manufacturing sites can shorten supply chains and reduce tariff exposure, but such shifts require investment in quality systems and regulatory validation that can extend timelines. Concurrently, software and data services, which are less tariff-exposed, have gained increased strategic importance as organizations seek to optimize existing hardware utilization and extract more value from legacy platforms. Overall, trade policy changes in 2025 have reinforced the need for flexible procurement strategies, strengthened supplier relationships, and a greater emphasis on supply chain transparency within transcriptomics operations.

An insightful breakdown of product, technological, application, and end-user segmentation that clarifies where capability gaps and value creation converge in transcriptomics

Segment-level dynamics reveal differentiated opportunities and operational considerations across product type, technology, application, and end-user segments that should inform strategic planning and resource allocation. Within product type, platforms encompass both benchtop sequencers and high-throughput sequencers, each catering to distinct throughput and throughput-cost trade-offs. Benchtop instruments are attractive for decentralized laboratories and diagnostic workflows that value rapid turnaround and simplified workflows, whereas high-throughput sequencers serve large-scale discovery programs and multi-sample clinical studies where cost per sample and instrument capacity are paramount. Reagents and consumables include cDNA synthesis kits, RNA extraction kits, and sequencing kits, with each category subject to stringent quality and lot-to-lot consistency requirements that directly influence downstream data integrity. Software and services cover data analysis software and data management services, which together form the backbone of reproducible, auditable pipelines required for cross-study comparisons and regulatory-grade evidence generation.

Across technologies, in situ hybridization offers spatial context that complements sequencing-based approaches, next generation sequencing provides breadth and depth for comprehensive transcriptome profiling, and quantitative real time PCR remains a workhorse for targeted validation and routine quantitation. These technologies serve distinct scientific questions and operational constraints, and they often coexist within the same programs to provide orthogonal validation and complementary insights. Regarding applications, stakeholders are deploying transcriptomics in biomarker discovery, drug discovery and development, gene expression profiling, and personalized medicine, where gene expression profiling itself spans bulk expression profiling and single-cell expression profiling. Bulk approaches remain relevant for tissue-level signals and established workflows, whereas single-cell profiling is unlocking cell-type specific expression patterns that reveal heterogeneity and rare cell populations.

Finally, end-user segmentation includes academic and research institutes, contract research organizations, hospitals and diagnostic laboratories, and pharmaceutical and biotechnology companies. Academic and research institutions continue to drive methodological innovation and exploratory studies, contract research organizations are scaling services to meet industry demand for outsourced expertise, hospitals and diagnostic labs are focused on clinical-grade workflows and compliance, and pharmaceutical and biotech firms prioritize throughput, standardization, and integration with discovery-to-clinic pipelines. Each segment exhibits unique purchasing cycles, quality expectations, and partnership models, and aligning product strategies with these differentiated requirements is essential for sustained commercial relevance.

A regionally nuanced perspective on infrastructure, regulatory expectations, and adoption pathways across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics shape infrastructure investments, regulatory expectations, and partnership opportunities across the transcriptomics domain, and a nuanced understanding of the Americas, Europe, Middle East & Africa, and Asia-Pacific is critical for effective market engagement. In the Americas, established research institutions and a dense biotechnology ecosystem continue to drive demand for high-throughput sequencing and advanced analytics, while translational initiatives and precision medicine programs in clinical networks create demand for validated workflows and integrated data management solutions. This region also houses significant reagent manufacturing capacity and a vibrant vendor landscape that supports rapid technology adoption.

Europe, Middle East & Africa presents a heterogeneous environment where strong regulatory frameworks in some European markets coexist with emerging clinical and research investments across the Middle East and Africa. In these markets, demand often centers on reproducibility, data protection compliance, and interoperability with national health infrastructures, creating an emphasis on certified workflows, local validation, and partnerships with regional service providers. Research consortia and collaborative networks in Europe also foster standardized protocols and cross-border data sharing, increasing the value of interoperable software and governance-ready data management services.

Asia-Pacific continues to exhibit rapid expansion of sequencing capacity, investment in local reagent manufacturing, and growing adoption of single-cell and spatial methods in both academic centers and industrial R&D. Many governments in the region are prioritizing biotech innovation, which accelerates translational collaborations and creates opportunities for suppliers who can support scale, localization of supply chains, and regulatory alignment. Across all regions, an emerging commonality is the prioritization of data integrity, workflow reproducibility, and supplier transparency, which together influence procurement decisions and partnership development.

Clear strategic patterns among platform, reagent, and software providers that reveal how competitive differentiation and partnership models are evolving within transcriptomics

Companies operating in the transcriptomics ecosystem are pursuing differentiated strategies that reflect their core competencies in platforms, reagents, or software and services, and these strategic choices illuminate likely competitive trajectories and partnership opportunities. Platform vendors are investing in instrument modularity, throughput scalability, and ease of use to address diverse laboratory footprints and reduce barriers to adoption. Firms that can demonstrate robust instrument performance across varied sample types and provide integrated consumable ecosystems gain an advantage with customers seeking turnkey solutions that minimize technical risk.

Reagent manufacturers are prioritizing lot consistency, robust supply chains, and compatibility across commonly used platforms. Given the sensitivity of downstream analyses to sample preparation, suppliers who can certify cross-platform compatibility and offer validated workflows for both bulk and single-cell profiling increase their appeal to translational and clinical customers. In parallel, providers of data analysis software and data management services are differentiating themselves through cloud-native architectures, compliance-ready features, and analytics accelerators that reduce time-to-insight. These companies are forging alliances with instrument and reagent suppliers to deliver bundled solutions that streamline onboarding and maintain data provenance.

Across the competitive landscape, value is accruing to organizations that combine technical excellence with service-oriented delivery models, including training, validation support, and long-term reagent availability commitments. Strategic M&A and partnership activity has centered on filling capability gaps-such as combining spatial technologies with sequencing workflows or integrating advanced analytics with laboratory informatics-to provide more complete offerings. For stakeholders evaluating potential partners or acquisition targets, emphasis should be placed on demonstrated quality control systems, regulatory readiness, and the ability to scale production and support international deployments.

Actionable, strategic recommendations for industry leaders to strengthen supply resilience, accelerate adoption, and align product roadmaps with application-driven demand

Industry leaders should adopt a set of pragmatic, actionable measures to maintain resilience and capture value as the transcriptomics landscape evolves. First, prioritize supplier diversification and qualification processes that assess not only price and lead times but also geographic exposure to trade policy risks, manufacturing redundancy, and quality system maturity. Investing in dual-source strategies for critical reagents and consumables reduces single-point-of-failure risk and provides leverage during procurement negotiations, while supplier scorecards aligned to regulatory and quality metrics facilitate faster qualification.

Second, pursue vertically integrated partnerships or bundled solution agreements that align platform performance with validated reagent kits and analytics pipelines. Such integrations lower adoption friction for end users and create stickier commercial relationships. When negotiating, include provisions for service-level agreements, reagent continuity, and data interoperability standards to protect operational continuity. Third, accelerate investments in data management and analytic infrastructure that enable reproducible pipelines and compliance-ready evidence generation. Cloud-first architectures, standardized pipelines, and audit-ready data governance will increasingly distinguish best-in-class deployments.

Fourth, align product roadmaps with application-specific needs such as single-cell profiling and spatial transcriptomics by offering validated end-to-end workflows that reduce the time and expertise required to generate actionable insights. Finally, incorporate tariff scenario planning and supply chain stress-testing into capital expenditure and procurement planning. Prepare contingency playbooks that include nearshoring options, buffer inventory strategies, and contract terms that mitigate the operational impact of trade policy shifts. Together, these actions will help organizations reduce risk, accelerate adoption, and sustain competitive differentiation.

A transparent explanation of the mixed-method research approach combining primary stakeholder interviews, technical triangulation, and supply chain scenario analysis used to derive the report's insights

This research draws on a mixed-method approach designed to capture the technological nuances, operational dynamics, and strategic responses shaping transcriptomics adoption. Primary inputs include structured interviews and targeted consultations with stakeholders across academia, contract research organizations, hospitals and diagnostic laboratories, and pharmaceutical and biotechnology companies, providing first-hand perspectives on procurement priorities, workflow pain points, and validation requirements. These conversations have been triangulated with secondary research encompassing peer-reviewed scientific literature, industry white papers, regulatory guidance documents, and supplier technical specifications to verify technological claims and performance characteristics.

Analytical steps included comparative capability mapping of platforms, reagents, and software offerings against application requirements such as throughput, sensitivity, and data interoperability. Supply chain analysis examined supplier footprints, manufacturing locations for critical consumables, and service network density to assess exposure to trade policy and logistics risk. The research also incorporated scenario analysis to explore the operational implications of tariff changes and supply chain disruptions, focusing on procurement strategies, inventory management, and potential nearshoring pathways.

Quality assurance measures included cross-validation of supplier claims with independent third-party evaluations where available, and consistency checks against documented regulatory submissions and validation studies. Limitations of the methodology are acknowledged; where empirical data are sparse, findings rely on expert consensus and documented vendor specifications, and readers are advised to supplement this report with primary technical validation in the context of specific laboratory workflows. Overall, the methodology blends qualitative insight with technical evaluation to produce actionable intelligence for decision-makers.

A concise conclusion synthesizing how integrated solutions, supplier resilience, and data governance will determine success in the evolving transcriptomics landscape

In conclusion, transcriptomics technologies are transitioning from niche research tools to foundational capabilities that enable a broad spectrum of scientific and clinical advances. The interplay among platforms, reagents, and software is creating an environment in which integrated solutions and disciplined data governance are essential to realize the full translational potential of gene expression profiling. As adoption expands, stakeholders must navigate technological choices that balance throughput, sensitivity, and operational complexity while ensuring that validation, reproducibility, and supplier resilience remain core priorities.

Trade policy shifts and tariff dynamics have underscored the importance of supply chain transparency and diversified sourcing strategies, prompting organizations to incorporate procurement resilience into long-term planning. Regionally differentiated adoption patterns further highlight the need for localization strategies-from regulatory-aligned offerings in Europe, Middle East & Africa to scale and manufacturing localization in Asia-Pacific and high-throughput deployments in the Americas. Lastly, companies that can deliver validated end-to-end workflows, shorten time-to-insight through advanced analytics, and mitigate operational risks through robust service models will capture disproportionate value as the field matures.

Decision-makers should therefore focus on building flexible supplier partnerships, investing in compliance-ready data infrastructure, and aligning product and service offerings to application-driven needs. By doing so, organizations will be positioned to accelerate discovery, improve clinical translation, and sustain competitive advantage in the rapidly evolving transcriptomics landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Transcriptomics Technologies Market, by Product Type

  • 8.1. Platforms
    • 8.1.1. Benchtop Sequencers
    • 8.1.2. High Throughput Sequencers
  • 8.2. Reagents & Consumables
    • 8.2.1. cDNA Synthesis Kits
    • 8.2.2. RNA Extraction Kits
    • 8.2.3. Sequencing Kits
  • 8.3. Software & Services
    • 8.3.1. Data Analysis Software
    • 8.3.2. Data Management Services

9. Transcriptomics Technologies Market, by Technology

  • 9.1. In Situ Hybridization
  • 9.2. Next Generation Sequencing
  • 9.3. Quantitative Real Time PCR

10. Transcriptomics Technologies Market, by Application

  • 10.1. Biomarker Discovery
  • 10.2. Drug Discovery & Development
  • 10.3. Gene Expression Profiling
    • 10.3.1. Bulk Expression Profiling
    • 10.3.2. Single Cell Expression Profiling
  • 10.4. Personalized Medicine

11. Transcriptomics Technologies Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Hospitals & Diagnostic Laboratories
  • 11.4. Pharmaceutical & Biotechnology Companies

12. Transcriptomics Technologies Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Transcriptomics Technologies Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Transcriptomics Technologies Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Transcriptomics Technologies Market

16. China Transcriptomics Technologies Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 10x Genomics, Inc.
  • 17.6. Agilent Technologies, Inc.
  • 17.7. Akoya Biosciences, Inc.
  • 17.8. Becton, Dickinson and Company
  • 17.9. Bio-Rad Laboratories, Inc.
  • 17.10. Bio-Techne Corporation
  • 17.11. Bruker Corporation
  • 17.12. Carl Zeiss AG
  • 17.13. Fluidigm Corporation
  • 17.14. Illumina, Inc.
  • 17.15. Oxford Nanopore Technologies Limited
  • 17.16. Pacific Biosciences of California, Inc.
  • 17.17. QIAGEN N.V.
  • 17.18. Roche Holding AG
  • 17.19. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY BENCHTOP SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY BENCHTOP SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY BENCHTOP SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY HIGH THROUGHPUT SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY HIGH THROUGHPUT SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY HIGH THROUGHPUT SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY CDNA SYNTHESIS KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY CDNA SYNTHESIS KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY CDNA SYNTHESIS KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY RNA EXTRACTION KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY RNA EXTRACTION KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY RNA EXTRACTION KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SEQUENCING KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SEQUENCING KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SEQUENCING KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY DATA MANAGEMENT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY DATA MANAGEMENT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY DATA MANAGEMENT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY QUANTITATIVE REAL TIME PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY QUANTITATIVE REAL TIME PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY QUANTITATIVE REAL TIME PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY BULK EXPRESSION PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY BULK EXPRESSION PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY BULK EXPRESSION PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SINGLE CELL EXPRESSION PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SINGLE CELL EXPRESSION PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SINGLE CELL EXPRESSION PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. GCC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 165. GCC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 166. GCC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 167. GCC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. GCC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. GCC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 170. GCC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. G7 TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 192. G7 TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 193. G7 TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 194. G7 TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. G7 TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. G7 TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 197. G7 TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. NATO TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. NATO TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 201. NATO TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 202. NATO TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 203. NATO TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. NATO TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. NATO TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 206. NATO TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)